Earnings call briefThird-quarter 2026
Biogen now expects approximately $50 million of acquired IPR&D in Q4
Biogen said it expects fourth-quarter VUMERITY revenue to be roughly flat sequentially or up approximately a mid single digit percentage from the prior-year quarter.
GetSignal Biogen BIIB
Biogen said on its third-quarter call that it expects fourth-quarter SPINRAZA revenue to be up approximately a mid single digit percentage from the prior-year fourth quarter.
Chief Financial Officer Robin C. Kramer said the company has repaid $600 million of term loans related to the Appellis acquisition and expects to repay the remaining $1.4 billion by the end of 2027.
Quotes from the call
“We also now expect approximately $50 million of acquired IPR&D in the fourth quarter.”
Key facts from the call
- Expected fourth-quarter acquired IPR&D
- approximately $50 million
- Expected fourth-quarter VUMERITY revenue
- roughly flat sequentially or up approximately a mid single digit percentage versus the fourth quarter of 25
- Appellis term loans repaid to date
- $600 million
- Remaining Appellis term loans expected to be repaid by end of 2027
- $1.4 billion
Source: Biogen's third-quarter 2026 earnings call, October 28, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
